Industry News Archives | International Rett Syndrome Foundation

June 19, 2025

Taysha Gene Therapies Updates on Part A Data, Plans for the Part B Pivotal Study, and FAQs (Community Letter)

Filter

Taysha

Taysha Shares Interim Clinical Data from Cohort One on FY23 Financial Results Call

DepYmed

DepYmed Receives Clearance from U.S. Food and Drug Administration to Initiate Phase 1 Clinical Trial for DPM-1003 for the Treatment of Rett Syndrome

Neurotech

All Phase I/II Rett Syndrome Patients to Receive NTI164 Treatment for a Total of 52 Weeks

Neurogene

Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial

Taysha

Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome

Taysha

Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome

Anavex

Anavex Announces Topline Results from Phase 2/3 EXCELLENCE Clinical Study in Pediatric Rett Syndrome

Neurogene

Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million

Neurogene

Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome